| Literature DB >> 25671110 |
Tim Mathes1, Thomas Jaschinski1, Dawid Pieper1.
Abstract
BACKGROUND: Non-adherence is widespread problem. Adherence is a crucial point for the success and the safe use of therapies. The objective of this overview (review of reviews) was to identify factors that influence adherence in chronic physical conditions.Entities:
Keywords: Adherence; Compliance; Oral medications; Oral therapy; Systematic review
Year: 2014 PMID: 25671110 PMCID: PMC4323150 DOI: 10.1186/2049-3258-72-37
Source DB: PubMed Journal: Arch Public Health ISSN: 0778-7367
Figure 1Flow- chart of study selection.
Study characteristics
| Study | Search period | Inclusion criteria* |
|---|---|---|
| Broekmans [ | Not limited – 12/2006 |
|
|
| ||
| Original research | ||
| Daley [ | Not limited – 01/2012 |
|
|
| ||
| All age ranges | ||
| Published in English | ||
| Presenting quantitative/qualitative data | ||
| Oosterom-Calo [ | Not limited – 08/2010 | ≥ |
| Quantitative results were reported | ||
| Studies of at least fair quality | ||
| Evaluations of interventions were not the main purpose | ||
| No descriptive study | ||
| No review paper | ||
| Published in English | ||
| Pasma [ | Not limited – 02/2011 |
|
| Used a reproducible definition or validated instrument to measure adherence | ||
| Provided a statistical measure to reflect the strength of the association between the determinant and adherence | ||
| No letters, editorials, reviews, RCTs, case reports, qualitative studies and opinion articles | ||
| Schrijvers [ | Not reported – 15/2012 |
|
|
| ||
| All age groups | ||
| Sinnott [ | 1946 – 09/2012 |
|
| Comparator group was the same population/similar population who either didn’t pay copayments or experienced no increase in copayment | ||
| The intervention was copayment; either an increase in an existing copayment or the introduction of a copayment (no other types of cost-sharing, for example co-insurance) | ||
| Studies included were randomised controlled trials, controlled before and after studies, interrupted time series designs, repeated measures designs, and cohort designs | ||
| Verbrugghe [ | NR |
|
| Age ≥ 18 | ||
| Strong or moderate methodological quality | ||
| Written in English, French, German or Dutch | ||
| Original research articles published between 1990 and April 2012 | ||
| Studies not conducted in developing countries | ||
| All study designs |
*Indication & medication marked bold.
Results of the study quality assessment
| Assessment question | á priori design | Two reviewers | Literature search | Status of publication | List of studies | Study characteristics | Conclusions | Combining findings | Publication bias | Conflict of interest |
|---|---|---|---|---|---|---|---|---|---|---|
| Study | ||||||||||
| Broekmans [ | + | ? | + | + | - | + | + | O | O | - |
| Daley [ | + | + | + | + | - | + | + | O | O | + |
| Oosterom-Calo [ | + | + | - | + | - | + | + | O | O | + |
| Pasma [ | + | ? | + | + | - | + | + | O | O | - |
| Schrijvers [ | + | - | + | ? | - | + | + | O | O | + |
| Sinnott [ | + | + | + | + | + | + | + | + | + | + |
| Verbrugghe [ | + | + | + | + | - | + | + | O | O | + |
+ = yes; − = no; O = not applicable; ? = unclear.
Evidence synthesis
| Factor | Relationship | ||
|---|---|---|---|
| Indication/therapy | Effect direction | Evidence for effect | |
|
| |||
| Education | Chronic pain |
|
|
| Parkinson | ↑ |
| |
| Heart failure* |
|
| |
| Oral cancer therapy | ↑ |
| |
| Employed | Inflammatory arthritis |
|
|
| Ethnic status | Parkinson | Ethnic minorities < others |
|
| Inflammatory arthritis | White > others |
| |
| Oral cancer therapy | Non-white > others |
| |
| Financial status/income | Parkinson | ↑ |
|
| Heart failure* |
|
| |
| Oral cancer therapy | ↑ |
| |
| Married/not living alone | Parkinson | ↑ |
|
| Oral cancer therapy | ↕ |
| |
| Social support | Heart failure* | ↕ |
|
| Inflammatory arthritis | ↑ |
| |
|
| |||
| Duration of therapy | Oral cancer therapy | ↓ |
|
| Frequency of intake | Parkinson | ↓ |
|
| Heart failure* |
|
| |
| Inflammatory arthritis |
|
| |
| Number of pills taken per day | Heart failure* |
|
|
| Different medications | Chronic pain | ↕ |
|
| Parkinson | ↓ |
| |
| Inflammatory arthritis | ↓ |
| |
| Oral cancer therapy | ↓ |
| |
| Heart failure* |
|
| |
| Taking medication at meals | Oral cancer therapy | ↑ |
|
|
| |||
| Duration of disease | Chronic pain |
|
|
| Inflammatory arthritis | ↓ |
| |
| Oral cancer therapy | ↓ |
| |
|
| |||
| Age | Chronic pain | ↑ |
|
| Parkinson | ↑ |
| |
| Heart failure* | ↑ |
| |
| 35-56 > others |
| ||
| Inflammatory arthritis | ↑ |
| |
| 55-64 > others |
| ||
| Hemophilia | ↑ |
| |
| Oral cancer therapy | ↕ |
| |
| Comorbidity (not specified) | Inflammatory arthritis | ↑ |
|
| Comorbidity (physical) | Heart failure* | ↕ |
|
| Comorbidity (mental) | Parkinson | ↓ |
|
| Heart failure* | ↓ |
| |
| Gender (female) | Chronic pain | ↑ |
|
| Heart failure* | ↕ |
| |
| Oral cancer therapy | ↕ |
| |
|
| |||
| Co-payments | Inflammatory arthritis | ↓ |
|
| Not restricted | ↓ |
| |
| Oral cancer therapy | ↓ |
| |
| Medication costs | Inflammatory arthritis | ↓ |
|
| Oral cancer therapy | ↓ |
| |
Effect direction.
↑: positive (all studies showed a positive effect on adherence); ↓: negative (all studies showed a negative effect on adherence); ↕: heterogenic (i.e. at least one study showed a contrary effect direction); O: unclear reported/ not reported.
Evidence for effect.
++: clear effect.
+: tendency of effect.
--: no effect.
-: tendency of no effect.
O: unclear effect.
*Inclusion criteria for studies: ≥50% of population are heart failure patients.